Quick Answer
Phathom Pharmaceuticals, Inc. reported Long Term Debt of $209.09 million for the year ending 2025.
- Phathom Pharmaceuticals, Inc. showed an increase of +3.8% in Long Term Debt from 2024 to 2025.
- This data is from Phathom Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $22.61 million | Q4 2019: $22.78 million | Q1 2020: $45.91 million | Q2 2020: $44.87 million | Q3 2020: $41.06 million | Q1 2021: $35.59 million | Q2 2021: $37.34 million | Q3 2021: $88.31 million | Q1 2022: $91.04 million | Q2 2022: $92.43 million | Q3 2022: $93.88 million | Q1 2023: $96.64 million | Q2 2023: $97.81 million | Q3 2023: $99.26 million | Q1 2024: $149.02 million | Q2 2024: $174.42 million | Q3 2024: $175.73 million | Q1 2025: $203.25 million | Q2 2025: $205.14 million | Q3 2025: $207.09 million.
- Over the full 8 years of available data (2019 to 2025), Phathom Pharmaceuticals, Inc.'s Long Term Debt has grown by 818.0%.
- Historical annual values: Fiscal year 2025: $209.09 million | Fiscal year 2024: $201.41 million | Fiscal year 2023: $137.84 million | Fiscal year 2022: $95.26 million | Fiscal year 2021: $89.67 million | Fiscal year 2020: $39.63 million | Fiscal year 2019: $22.78 million | Fiscal year 2019: $22.78 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: